Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report published on Wednesday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ:ADXS opened at $0.03 on Wednesday. The company has a market cap of $1.28 million, a price-to-earnings ratio of 0.00 and a beta of 1.68. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $0.78. The stock has a fifty day simple moving average of $0.03 and a 200-day simple moving average of $0.04.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.